Your browser doesn't support javascript.
APOL1 Risk Variants, Acute Kidney Injury, and Death in Participants With African Ancestry Hospitalized With COVID-19 From the Million Veteran Program.
Hung, Adriana M; Shah, Shailja C; Bick, Alexander G; Yu, Zhihong; Chen, Hua-Chang; Hunt, Christine M; Wendt, Frank; Wilson, Otis; Greevy, Robert A; Chung, Cecilia P; Suzuki, Ayako; Ho, Yuk-Lam; Akwo, Elvis; Polimanti, Renato; Zhou, Jin; Reaven, Peter; Tsao, Philip S; Gaziano, J Michael; Huffman, Jennifer E; Joseph, Jacob; Luoh, Shiuh-Wen; Iyengar, Sudha; Chang, Kyong-Mi; Casas, Juan P; Matheny, Michael E; O'Donnell, Christopher J; Cho, Kelly; Tao, Ran; Susztak, Katalin; Robinson-Cohen, Cassianne; Tuteja, Sony; Siew, Edward D.
  • Hung AM; Tennessee Valley Healthcare System, Nashville Campus, Nashville.
  • Shah SC; Division of Nephrology & Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Bick AG; GI Section, VA San Diego Healthcare System, San Diego, California.
  • Yu Z; Division of Gastroenterology, University of California, San Diego, San Diego.
  • Chen HC; Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Hunt CM; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Wendt F; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Wilson O; Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina.
  • Greevy RA; VA Cooperative Studies Program Epidemiology Center, Durham VA Health Care System, Durham, North Carolina.
  • Chung CP; Department of Psychiatry, Yale University School of Medicine, West Haven, Connecticut.
  • Suzuki A; VA CT Healthcare Center, West Haven, Connecticut.
  • Ho YL; Division of Nephrology & Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Akwo E; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Polimanti R; Division of Rheumatology and Division of Clinical Pharmacology, Vanderbilt University Medical Center, Rheumatology Section, Veterans Affairs, Nashville, Tennessee.
  • Zhou J; Division of Gastroenterology, Duke University Medical Center, Durham, North Carolina.
  • Reaven P; VA Cooperative Studies Program Epidemiology Center, Durham VA Health Care System, Durham, North Carolina.
  • Tsao PS; Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston.
  • Gaziano JM; Division of Nephrology & Hypertension, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Huffman JE; Department of Psychiatry, Yale University School of Medicine, West Haven, Connecticut.
  • Joseph J; VA CT Healthcare Center, West Haven, Connecticut.
  • Luoh SW; Department of Epidemiology and Biostatistics, University of Arizona, Phoenix.
  • Iyengar S; Phoenix VA Health Care System, Phoenix, Arizona.
  • Chang KM; Phoenix VA Health Care System, Phoenix, Arizona.
  • Casas JP; Division of Endocrinology, Department of Medicine, University of Arizona, Phoenix.
  • Matheny ME; Epidemiology Research and Information Center (ERIC), VA Palo Alto Health Care System, Palo Alto, California.
  • O'Donnell CJ; Department of Medicine, Stanford University School of Medicine, Palo Alto, California.
  • Cho K; Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston.
  • Tao R; Division of Aging, Brigham & Women's Hospital, Boston, Massachusetts.
  • Susztak K; Center for Population Genomics, Massachusetts Veterans Epidemiology Research & Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts.
  • Robinson-Cohen C; Cardiology Section, Veterans Affairs Boston, Boston, Massachusetts.
  • Tuteja S; Division of Cardiovascular Medicine, Brigham & Women's Hospital, Boston, Massachusetts.
  • Siew ED; VA Portland Health Care System, Portland, Oregon.
JAMA Intern Med ; 182(4): 386-395, 2022 04 01.
Article in English | MEDLINE | ID: covidwho-1653126
ABSTRACT
IMPORTANCE Coronavirus disease 2019 (COVID-19) confers significant risk of acute kidney injury (AKI). Patients with COVID-19 with AKI have high mortality rates.

OBJECTIVE:

Individuals with African ancestry with 2 copies of apolipoprotein L1 (APOL1) variants G1 or G2 (high-risk group) have significantly increased rates of kidney disease. We tested the hypothesis that the APOL1 high-risk group is associated with a higher-risk of COVID-19-associated AKI and death. DESIGN, SETTING, AND

PARTICIPANTS:

This retrospective cohort study included 990 participants with African ancestry enrolled in the Million Veteran Program who were hospitalized with COVID-19 between March 2020 and January 2021 with available genetic information. EXPOSURES The primary exposure was having 2 APOL1 risk variants (RV) (APOL1 high-risk group), compared with having 1 or 0 risk variants (APOL1 low-risk group). MAIN OUTCOMES AND

MEASURES:

The primary outcome was AKI. The secondary outcomes were stages of AKI severity and death. Multivariable logistic regression analyses adjusted for preexisting comorbidities, medications, and inpatient AKI risk factors; 10 principal components of ancestry were performed to study these associations. We performed a subgroup analysis in individuals with normal kidney function prior to hospitalization (estimated glomerular filtration rate ≥60 mL/min/1.73 m2).

RESULTS:

Of the 990 participants with African ancestry, 905 (91.4%) were male with a median (IQR) age of 68 (60-73) years. Overall, 392 (39.6%) patients developed AKI, 141 (14%) developed stages 2 or 3 AKI, 28 (3%) required dialysis, and 122 (12.3%) died. One hundred twenty-five (12.6%) of the participants were in the APOL1 high-risk group. Patients categorized as APOL1 high-risk group had significantly higher odds of AKI (adjusted odds ratio [OR], 1.95; 95% CI, 1.27-3.02; P = .002), higher AKI severity stages (OR, 2.03; 95% CI, 1.37-2.99; P < .001), and death (OR, 2.15; 95% CI, 1.22-3.72; P = .007). The association with AKI persisted in the subgroup with normal kidney function (OR, 1.93; 95% CI, 1.15-3.26; P = .01). Data analysis was conducted between February 2021 and April 2021. CONCLUSIONS AND RELEVANCE In this cohort study of veterans with African ancestry hospitalized with COVID-19 infection, APOL1 kidney risk variants were associated with higher odds of AKI, AKI severity, and death, even among individuals with prior normal kidney function.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Veterans / Acute Kidney Injury / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Variants Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: JAMA Intern Med Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Veterans / Acute Kidney Injury / COVID-19 Type of study: Cohort study / Observational study / Prognostic study Topics: Variants Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: JAMA Intern Med Year: 2022 Document Type: Article